STAT3 and lymphoma: Furthermore, in mantle cell lymphoma, SB-225002 overcame drug resistance by inhibiting the activation of Akt, STAT3, and p38 signaling pathways and reprogramming lymphoma-associated macrophages (Sun et al., 2025).